CANCER CENTER SUPPORT GRANT

癌症中心支持补助金

• 批准号: 10514669
• 负责人: JOSEPH P. UBERTI
• 金额: $ 11.5万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-08 至 2025-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10514669
• 关键词: Address; African American; African American population; American Cancer Society; Area; Attention; Basic Science; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Hospital; Cancer Intervention; Cancer Patient; Caring; Catchment Area; Censuses; Cessation of life; Cities; Clinic; Clinical Research; Communication; Communities; Compassion; Comprehensive Cancer Center; County; Devices; Diagnosis; Early Diagnosis; Education; Epidemiology; Etiology; Family; Foundations; Funding; Future; Goals; Grant; Healthcare; Home; Household; Income; Institutes; Intervention; Laboratory Research; Lead; Location; Malignant Neoplasms; Medically Underserved Area; Michigan; Minority; Minority Enrollment; Minority Groups; Mission; Modeling; Molecular; Morbidity - disease rate; National Clinical Trials Network; Pathway interactions; Patient Care; Patients; Peer Review; Persons; Physicians; Population; Population Heterogeneity; Population Research; Population Study; Poverty; Prevention; Process; Protocols documentation; Public Health; Quality of Care; Research; Research Contracts; Research Institute; Research Personnel; Research Project Grants; Resource Sharing; Resources; Secure; Socioeconomic Factors; Source; Therapeutic; Therapeutic Intervention; Therapeutic Studies; Tissues; Translational Research; Treatment Protocols; Tumor Biology; United States; United States Health Resources and Services Administration; Universities; Work; anticancer research; base; cancer care; cancer risk; care delivery site; care providers; clinical care; disadvantaged population; ethnic minority; member; metropolitan; molecular imaging; mortality; multidisciplinary; new technology; novel therapeutics; operation; participant enrollment; patient engagement; programs; racial and ethnic; racial minority; social disparities; socioeconomic disadvantage; suburb; success; tool; treatment center; tumor microenvironment

OVERALL - ABSTRACT The Karmanos Cancer Institute (KCI), founded in 1943, is a not-for-profit, cancer-only research and patient care organization in partnership with Wayne State University (WSU) in Michigan. The designation by the NCI as a Comprehensive Cancer Center was achieved in 1978. KCI operates its wholly-owned, free-standing, cancer hospital and ambulatory clinics (KCC) in Detroit and in Farmington Hills, a suburban location. As a member of McLaren Health Care (MHC), a not-for profit health care corporation, KCI is also responsible for cancer research, quality of care, and cancer care operations in all facilities owned and operated by MHC. Our catchment area covers 46 of Michigan’s 83 counties with a population of 6.7 million people. This catchment area is home to 95% of our patients, and KCI sees one-third of all new cancer patients in the catchment area. The Southeast region of our catchment area includes the metropolitan Detroit, defined as a tri-county area (Wayne, Oakland, Macomb) and home to 3.86 million residents. The city of Detroit is the largest city in the state (672,000 residents). Detroit is a resource-challenged area, with a median household income of $27,838 and 37.9% of residents living below poverty level, compared to 16.7% in the state of Michigan. The majority of census tracts in the city of Detroit are medically underserved areas based on HRSA definitions. About 79% of Detroit residents identify as African American, a group that disproportionately carries KCI catchment area’s cancer burden. In 2018, KCI physicians saw approximately 12,000 new cancer patients (including approximately 8,000 analytic cases), with approximately 15% representing minority groups. The annual number of new cancer cases in these 46 counties is approximately 39,000 and has not changed significantly since 2014. In FY19, our minority accrual to interventional treatment protocols was 24.2%. We have a long standing scientific and patient care commitment to the African American population of southeastern Michigan, as exemplified in the broad array of studies focused on molecular, therapeutic, and social disparities. This application profiles the strengths and successes of our four scientific Programs, Tumor Biology and Microenvironment (TBM, 01), Molecular Imaging (MI, 02), Molecular Therapeutics (MT, 03), and Population Studies and Disparities Research (PSDR, 04). The research efforts of these Programs is supported by nine Shared Resources (Cores), including one developing Core. As of December 2019, KCI’s 135 scientific members have secured total annual direct project funding of $ 63,162,159 (an increase of 12.3% from 2015) of which $21,864,688 is peer reviewed funding and $11,743,830 is from the NCI.

总体-摘要 Karmanos癌症研究所（KCI）成立于1943年，是一家非营利性的癌症研究和患者治疗机构。 护理组织与密歇根州的韦恩州立大学（WSU）合作。国家癌症研究所指定的 1978年建成了综合癌症中心。KCI经营其全资拥有的，独立的， 底特律和郊区法明顿山的癌症医院和门诊诊所（KCC）。作为 McLaren Health Care（MHC）是一家非营利性医疗保健公司，KCI还负责 癌症研究，护理质量，以及MHC拥有和经营的所有设施中的癌症护理操作。我们 集水区覆盖密歇根州83个县中的46个，人口670万。这个集 该地区是我们95%的患者的家园，KCI在集水区看到了所有新癌症患者的三分之一。 我们的集水区的东南部地区包括底特律大都市，定义为三县区 （韦恩，奥克兰，马科姆）和386万居民的家园。底特律市是美国最大的城市， 州（672，000居民）。底特律是一个资源短缺的地区，家庭收入中位数为27，838美元 37.9%的居民生活在贫困线以下，而密歇根州为16.7%。大多数 根据HRSA的定义，底特律市的人口普查区是医疗服务不足的地区。约79%的 底特律居民认为是非洲裔美国人，这是一个不成比例地携带KCI集水区的群体。 癌症负担 在2018年，KCI医生看到了大约12，000名新的癌症患者（其中包括大约8，000名分析患者）。 其中约15%为少数民族。每年的新癌症病例数 这46个县约为39 000个，自2014年以来没有发生重大变化。在2019财年，我们的少数 介入治疗方案的获得率为24.2%。我们有一个长期的科学和耐心的护理 对密歇根州东南部非洲裔美国人的承诺，如广泛的 研究集中在分子、治疗和社会差异上。该应用程序概述了优势和 我们的四个科学项目取得了成功，肿瘤生物学和微环境（TBM，01），分子 成像（MI，02），分子治疗（MT，03），人口研究和差异研究 (PSDR，04）。这些计划的研究工作得到了九个共享资源（核心）的支持， 包括一个发展中的核心。截至2019年12月，KCI的135名科学成员已经获得了 年度直接项目资金为63，162，159美元（比2015年增加12.3%），其中21，864，688美元是同行 审查资金和11，743，830美元来自NCI。